A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the impact of IPI-504 in combination with docetaxel
to placebo in combination with docetaxel on life expectancy in patients with Non Small Cell
Lung cancer (NSCLC). Docetaxel is an approved chemotherapy for NSCLC. An additional goal of
the study is to determine the effect of IPI-504, in combination with docetaxel, verses
placebo in, combination with docetaxel, on the growth of cancer